General Inception News Today

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – Si...

ASU ranks among the Top 5 research institutions without a medical school for inventions, U.S. patents secured and startups launched.

/PRNewswire/ -- OmniSync Incorporated has been awarded a Small Business Innovation Research (SBIR) Phase III contract by the US Air Force to deliver and...

San Diego-based OmniSync, which is backed by Govtech Fund, Longley Capital, General Inception, Keshif Ventures, and angels, said it has received a SBIR Phase III contract. The contract comes rom the US Air

Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

It’s called a pangenome, and it could explain the DNA that makes each of us unique.

/PRNewswire/ -- OmniSync has been awarded a 5-year Phase III commercialization contract by the Office of Small Business Innovation Research (SBIR)/Small...

General Inception, the first-ever Igniter, today announced its multi-year strategic partnership with SATT Paris-Saclay to identify and help scientific innovators from its member research laboratories

/PRNewswire/ -- OmniSync Incorporated announces that it has been selected by AFWERX for a SBIR Phase II contract in the amount of $757,428 focused on adapting...